front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |34 |35 |36 |review |
Here we examine key adipocyte-derived bioactive substances
(‘adipokines’) in more detail.
Adiponectin exerts a number of protective actions in the
vasculature, including inhibition of foam
cell formation and vascular remodelling, both important steps in
the formation of an atherosclerotic plaque. This hormone also improves
insulin sensitivity and opposes the development of hyperglycaemia, and
is therefore anti-diabetic as well as anti-atherosclerotic in nature.
IL-6 is a systemic
inflammatory hormone that exerts adverse, pro-atherogenic effects in the
vasculature. IL-6 also exacerbates insulin resistance
and is therefore both pro-atherogenic and pro-diabetic.
TNFa
is a paracrine regulator in adipocytes. TNFa
-induced reductions in insulin sensitivity in adipocytes are partly
responsible for the increased free fatty acid production and
hypertriglyceridaemia characteristic of abdominal
obesity.
Increased PAI-1 secretion
by intra-abdominal adipocytes shifts the balance of fibrinolysis
towards a procoagulant state, increasing the risk of a morbid
thromboembolic event
|